Galapagos NV

Galapagos appoints Paul Stoffels as Chief Executive Officer

26 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN    

18 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plan

13 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference

06 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

03 Dec 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

22 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis

15 Nov 2021 09:45:07 By Nasdaq GlobeNewswire

Galapagos reports commercial and operational progress at Q3 financial results

04 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress

04 Oct 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease

04 Oct 2021 00:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

20 Sep 2021 15:01:00 By Nasdaq GlobeNewswire

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

17 Sep 2021 06:15:00 By Nasdaq GlobeNewswire

Galapagos announces planned retirement of CEO

30 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos reports H1 financial results with refocused pipeline and operational progress

05 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

14 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

14 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

10 Jul 2021 04:10:00 By Nasdaq GlobeNewswire

Galapagos announces departure of CSO Piet Wigerinck later this year

22 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

07 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

SELECTION study on filgotinib in ulcerative colitis published in The Lancet

04 Jun 2021 00:01:00 By Nasdaq GlobeNewswire